Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ribapharm Inc.filedCriticalRibapharm Inc.
Publication of YU61302ApublicationCriticalpatent/YU61302A/sh
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Opisana su nova jedinjenja nalozi nukleozida. Nova jedinjenja, ili njihovi farmaceutski prihvatljivi estri ili soli, mogu da se koriste u farmaceutskim preparatima, a ti preparati se mogu koristiti za tretiranje infekcije, infestacije, neoplazma ili autoimune bolesti. Nova jedinejnja mogu takođe da se koriste za modulisanje aspekata imuno sistema, uključujući modulisanje aktivnosti Tipa 1 i Tipa 2.[Novel nucleoside analog compounds are disclosed. The novel compounds or pharmaceutically acceptable esters or salts thereof may be used in pharmaceutical compositions, and such compositions may be used to treat an infection, an infestation, a neoplasm, or an autoimmune disease. The novel compounds may also be used to modulate aspects of the immune system, including modulation of Type 1 and Type 2 activity.
YU61302A2000-02-152001-02-15Analozi nukleozida sa modifikovanom karboksamidinskom bicikličnom bazom
YU61302A
(sh)